Drug intelligence / Profile preview

Daxalipram

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral, Transdermal, Subcutaneous

Overview

Daxalipram is a small molecule identified as a type IV phosphodiesterase (PDE4) inhibitor. It has been investigated in preclinical studies for its potential therapeutic effects, including alleviating experimental colitis in mice, reducing ethanol intake and preference in C57BL/6J mice, and triggering ovulation in follicle-stimulating hormone-primed rats. It is primarily available for research use.

Other names: Mesopram

Targets

PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)

Beyond the preview

Go deeper on Daxalipram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daxalipram.

Explore the full profile